CClinicalTrials.gg
RecruitingNCT05200923PEER 2Updated Mar 3, 2026

Pelvic Health Electrically Evoked Recording (PEER) 2 Study

An interventional study of Sacral Neuromodulation in Overactive Bladder, Fecal Incontinence and Urinary Retention, sponsored by MedtronicNeuro. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by MedtronicNeuro · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To collect physiological signals at several timepoints during the therapy evaluation period.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this non-applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

02

Conditions studied

  • Overactive Bladder
  • Fecal Incontinence
  • Urinary Retention
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Overactive Bladder Criteria Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated informed consent
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation
  6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.
  7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Non-Obstructive Urinary Retention Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated informed consent
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation
  6. Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Fecal Incontinence Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated informed consent
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation
  6. Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling)

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Exclusion criteria

Exclusion Criteria:

Overactive Bladder Criteria Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. History of diabetes unless the diabetes is well-controlled through diet and/or medications
  6. Have symptomatic urinary tract infection (UTI)
  7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
  8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study
  9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  12. Women who are pregnant or planning to become pregnant
  13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
  14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Non-Obstructive Urinary Retention Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. History of diabetes unless the diabetes is well-controlled through diet and/or medications
  6. Have symptomatic urinary tract infection (UTI)
  7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  10. Women who are pregnant or planning to become pregnant
  11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
  12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Fecal Incontinence Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. Have uncorrected high grade internal rectal prolapse
  6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  9. Women who are pregnant or planning to become pregnant
  10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Pelvic health Electrically Evoked Recording (PEER) 2 Study

    Collect physiological signals

    Device: Sacral Neuromodulation

Interventions

  • DeviceSacral Neuromodulation

    Sacral neuromodulation delivers electrical stimulation to a sacral nerve

05

What researchers measure

Primary outcomes

  1. Number of subjects with physiological signals collected at each timepoint

    The proportion of subjects with evaluable signals will be summarized at each timepoint

    Time frame: 1 day to 7 months

06

Study locations

5 of 7 sites recruiting
  • Indiana University Health Methodist Research Institute
    Indianapolis, Indiana 46202, United States
    • Andi Nowakowski · Contact · amnowako@iu.edu · 317-278-6752
    • Charles Powell · Principal investigator
    Recruiting
  • LSUHSC Department of Urology
    New Orleans, Louisiana 70112, United States
    Withdrawn
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
    Recruiting
  • Mayo Clinic Urology/Urogynecology Department
    Rochester, Minnesota 55905, United States
    Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    • Hachem Ziadeh · Contact · Hachem.ziadeh@uhhospitals.org · 440-470-8830
    • David Sheyn · Principal investigator
    • Adonis Hijaz · Sub investigator
    • Joseph Henderson · Sub investigator
    • Anne Sammarco · Sub investigator
    Recruiting
  • OhioHealth Physician's Group Urology
    Hilliard, Ohio 43026-2050, United States
    Recruiting
  • DHR Health Institute for Research and Development
    Edinburg, Texas 78539, United States
    Completed
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05200923
Lead sponsor
MedtronicNeuro
Responsible party
Sponsor
First posted
Jan 21, 2022
Start date
Jan 18, 2022
Primary completion
Dec 18, 2026 (estimated)
Completion
Dec 18, 2026 (estimated)
Last update
Mar 3, 2026

Study contacts

Katherine Peterson
Contact
katherine.r.peterson@medtronic.com
414-704-4065
Katherine Peterson
study director · Medtronic Pelvic Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion